Literature DB >> 11474498

Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome.

J M Limacher1, T Frebourg, S Natarajan-Ame, J P Bergerat.   

Abstract

A woman with a family history of brain tumors in her daughter and sister presented with a breast cancer. She subsequently developed two metachronous primary tumors: a small-cell lung cancer and a colon carcinoma. These tumors arose within the internal mammary radiotherapy field and within the field irradiated for ovariolysis. The p53 gene was analyzed in whole blood lymphocytes using a functional assay developed in yeast Saccharomyces cerevisiae, which tests the transcriptional competence of p53. DNA from the colon cancer cells was analyzed by polymerase chain reaction and sequencing. The patient had a germline-inactivating p53 mutation, confirming the diagnosis of Li-Fraumeni syndrome (LFS). The colon tumor and the lung tumor both conserved the mutant p53 allele but had lost the wild-type allele. This observation and the experimental data suggest an abnormal sensitivity of LFS patients to radiogenic carcinogenesis. The indications and extent of radiotherapy in patients with a clinical or molecular diagnosis of LFS should be discussed individually and should take into account the risk of secondary neoplasms arising in the radiation fields. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11474498     DOI: 10.1002/ijc.1021

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  40 in total

Review 1.  Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.

Authors:  D G R Evans; J M Birch; R T Ramsden; S Sharif; M E Baser
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

Review 2.  Genotype phenotype correlation in Li-Fraumeni syndrome kindreds and its implications for management.

Authors:  R N Moule; S G Jhavar; R A Eeles
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

Review 3.  Second malignant neoplasms and cardiovascular disease following radiotherapy.

Authors:  Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice
Journal:  J Natl Cancer Inst       Date:  2012-02-06       Impact factor: 13.506

4.  Metachronous medulloblastoma and glioblastoma: Implications for clinical and technical aspects of re-irradiation.

Authors:  Vivek Verma; Rajesh R Kulkarni; Abhijeet R Bhirud; Nathan R Bennion; Rodney D McComb; Chi Lin
Journal:  Rep Pract Oncol Radiother       Date:  2015-11-21

5.  Lack of toxicity in a patient with germline TP53 mutation treated with radiotherapy.

Authors:  P Wong; K Han
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

6.  Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.

Authors:  Anh N Le; Joanna Harton; Heena Desai; Jacquelyn Powers; Kristin Zelley; Angela R Bradbury; Katherine L Nathanson; Payal D Shah; Abigail Doucette; Gary M Freedman; Peter Gabriel; Susan M Domchek; Suzanne P MacFarland; Kara N Maxwell
Journal:  Breast Cancer Res Treat       Date:  2020-04-03       Impact factor: 4.872

7.  Prevalence of germline TP53 mutations in HER2+ breast cancer patients.

Authors:  Michelle G Rath; Serena Masciari; Rebecca Gelman; Alexander Miron; Penelope Miron; Kathleen Foley; Andrea L Richardson; Ian E Krop; Sigitas J Verselis; Deborah A Dillon; Judy E Garber
Journal:  Breast Cancer Res Treat       Date:  2013-04-12       Impact factor: 4.872

Review 8.  Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.

Authors:  Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng
Journal:  Nat Rev Clin Oncol       Date:  2013-03-26       Impact factor: 66.675

9.  Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.

Authors:  Laurent Castéra; Sophie Krieger; Antoine Rousselin; Angélina Legros; Jean-Jacques Baumann; Olivia Bruet; Baptiste Brault; Robin Fouillet; Nicolas Goardon; Olivier Letac; Stéphanie Baert-Desurmont; Julie Tinat; Odile Bera; Catherine Dugast; Pascaline Berthet; Florence Polycarpe; Valérie Layet; Agnes Hardouin; Thierry Frébourg; Dominique Vaur
Journal:  Eur J Hum Genet       Date:  2014-02-19       Impact factor: 4.246

10.  Differential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell model.

Authors:  A Kathleen McClendon; Jeffry L Dean; Adam Ertel; Erik S Knudsen
Journal:  PLoS One       Date:  2010-01-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.